Compare CHPT & AGEN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CHPT | AGEN |
|---|---|---|
| Founded | 2007 | 1994 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Industrial Specialties | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 190.2M | 147.4M |
| IPO Year | 2019 | 1999 |
| Metric | CHPT | AGEN |
|---|---|---|
| Price | $7.55 | $3.50 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 9 | 2 |
| Target Price | $9.25 | ★ $14.50 |
| AVG Volume (30 Days) | 483.1K | ★ 744.4K |
| Earning Date | 06-03-2026 | 05-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 100.00 |
| EPS | N/A | ★ 1.02 |
| Revenue | ★ $411,224,000.00 | $42,877,086.00 |
| Revenue This Year | $4.18 | $107.63 |
| Revenue Next Year | $16.63 | N/A |
| P/E Ratio | ★ N/A | $3.32 |
| Revenue Growth | N/A | ★ 89.95 |
| 52 Week Low | $0.58 | $2.71 |
| 52 Week High | $12.62 | $7.34 |
| Indicator | CHPT | AGEN |
|---|---|---|
| Relative Strength Index (RSI) | 64.56 | 48.00 |
| Support Level | $7.30 | $2.93 |
| Resistance Level | $12.62 | $4.72 |
| Average True Range (ATR) | 0.51 | 0.24 |
| MACD | 0.12 | 0.01 |
| Stochastic Oscillator | 77.40 | 68.46 |
ChargePoint Holdings Inc designs, develops, and markets networked electric vehicle charging system infrastructure and cloud-based services that enable charging systems owners, charge point operators, to manage their Networked Charging Systems, and to enable drivers to locate, reserve and authenticate Networked Charging Systems and to transact EV charging sessions on those systems. The company's hardware product lineup includes solutions across home, commercial, and fast-charging applications. The company derives the majority of its revenue from the United States.
Agenus Inc is a clinical-stage biotechnology company focused on discovering and developing immunotherapies for cancer and infectious diseases. Its primary business is immuno-oncology (I-O), where it advances antibody-based programs designed to activate innate and adaptive immunity, overcome tumor immune evasion, and expand the number of patients who may benefit from immunotherapy. The Company's clinical program includes botensilimab (BOT or AGEN1181), both as a monotherapy and in combination with balstilimab (BAL), alongside a portfolio of other clinical-stage immuno-oncology assets that may be used independently or in combination therapies. The Company operates in the United States, which contributes the majority of its revenue, as well as in other international markets.